Discover

Back to filter

Related topics

qPCR? Learn more about qTOWER³ Product Family – Product Animation

Analytik Jena

Apr 12, 2021

The qTOWER³ product family guarantees well-founded real-time results as it benefits from peerless temperature control...

SARS-CoV-2 N Protein Antigen Test as new Quanterix tool in ultrasensitive biomarkers detection

Quanterix

Apr 12, 2021

Digital health solution, Simoa, is changing the way in which the biology of health and disease is studied by giving...

Observe the movement of live cells that make up living tissue in vivo!

IVIM Technology

Apr 12, 2021

IntraVital Microscopy is a technique that enables you to directly observe the movement of live cells that make up...

Single-cell DNA Analysis of a Novel Acute Erythroid Leukemia CRISPR Induced Mouse Model

Mission Bio

Apr 12, 2021

Single-cell DNA Analysis of a Novel Acute Erythroid Leukemia (AEL) CRISPR Induced Mouse Model.
Assessment of
...

Developing tools for multiplex to single EV analysis pipelines

Cytek Biosciences

Apr 12, 2021

Extracellular vesicles (EVs) are lipid spheres released from cells. EVs express proteins...

SARS-CoV-2 detection workflow in wastewater- Analytik Jena and project in Japan

Analytik Jena

Apr 12, 2021

In 2020 Analytik Jenas real-time PCR thermal cyclers of the qTOWER³ series even supported one of the first SARS-CoV-2...

Observe the movement of live cells that make up living tissue in vivo

IVIM Technology

Apr 8, 2021

IntraVital Microscopy is a technique that enables you to directly observe the movement of...

Cytek webinar : Improved flow cytometry assay resolution with autofluorescence extraction

Cytek Biosciences

Mar 30, 2021

The power of autofluorescence extraction in the detection of dim fluorescence on highly...

Innovation never takes a break with IncuCyte

Sartorius

Mar 11, 2021

Analyze your cells for days, weeks or even months as they sit stationary in the stable...

Show all topics (10)

Preclinical cardiac safety assesment

Mar 22, 2016

Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.

Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.

The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.

The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.

Application
Product news

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

Cardio Instrument is a high-resolution system for label-free-dual-mode monitoring of cardiomyocyte and cardiotoxicity testing

show detail

The new CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey